Your browser doesn't support javascript.
loading
The broader benefits of vaccines: methodologies for inclusion in economic evaluation.
Simoens, Steven; Tubeuf, Sandy; Dauby, Nicolas; Ethgen, Olivier; Marbaix, Sophie; Willaert, Marjan; Luyten, Jeroen.
Affiliation
  • Simoens S; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Tubeuf S; Institute of Health and Society (IRSS), Université Catholique de Louvain (UClouvain), Brussels, Belgium.
  • Dauby N; Institute of Economic and Social Research (IRES), Université Catholique de Louvain (UClouvain), Brussels, Belgium.
  • Ethgen O; Department of Infectious Diseases, CHU Saint-Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Marbaix S; School of Public Health, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Willaert M; Department of Public Health, Epidemiology and Health Economics, Faculty of Medicine, University of Liège, Liège, Belgium.
  • Luyten J; SERFAN Innovation, Namur, Belgium.
Expert Rev Vaccines ; 23(1): 779-788, 2024.
Article in En | MEDLINE | ID: mdl-39136368
ABSTRACT

BACKGROUND:

As the societal value of vaccines is increasingly recognized, there is a need to examine methodological approaches that could be used to integrate these various benefits in the economic evaluation of a vaccine. RESEARCH DESIGN AND

METHODS:

A literature review and two expert panel meetings explored methodologies to value herd immunity, health spillover effects (beyond herd immunity), impact on antimicrobial resistance, productivity, and equity implications of vaccines.

RESULTS:

The consideration of broader benefits of vaccines in economic evaluation is complicated and necessitates technical expertise. Whereas methodologies to account for herd immunity and work productivity are relatively well established, approaches to investigate equity implications are developing and less frequently applied. Modeling the potential impact on antimicrobial resistance not only depends on the multi-faceted causal relationship between vaccination and resistance but also on data availability.

CONCLUSIONS:

Different methods are available to value the broad impact of vaccines, and it is important that analysts are aware of their strengths and limitations and justify their choice of method. In the future, we expect that an increasing number of economic evaluations will consider the broader benefits of vaccines as part of their base-case analysis or in sensitivity analyses.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccines / Vaccination / Cost-Benefit Analysis / Immunity, Herd Limits: Humans Language: En Journal: Expert Rev Vaccines Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article Affiliation country: Belgium Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Vaccines / Vaccination / Cost-Benefit Analysis / Immunity, Herd Limits: Humans Language: En Journal: Expert Rev Vaccines Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article Affiliation country: Belgium Country of publication: United kingdom